Maitreya Medicare is equipped with its Cathlab and two advanced Super Specialty Operating Theatres, with Laminar Air Flow and HEPA Filters. Additionally, they offer a 20-bed Intensive Care Unit equipped with ECMO and CRRT, along with essential support services like Pathology and Radiology, including CT scans.
Over the years, Maitreya Medicare's hospital has seen growth, expanding from 67 beds in 2021 to 100 beds in 2022 and now reaching a capacity of 125 beds in 2023.
Maitreya Medicare's has earned the NABH certification for both Maitreya Medicare Limited and their upcoming subsidiary, Maitreya Hospital Pvt Ltd in Valsad, Gujarat, which will also adhere to NABH standards.
Maitreya Medicare is currently in the process of establishing a 125-bed multi-specialty hospital in Valsad, Gujarat. This facility in Valsad City will be staffed by full-time super-specialist doctors, particularly in cardiology, neurology, and nephrology, providing advanced tertiary care services.
Maitreya Medicare heavily relies on healthcare professionals, such as doctors, nurses, and consultants. The loss of these professionals or the inability to attract and retain them could harm the company's business and financial results.
Legal proceedings involving the company may negatively impact its business, financial condition, and results of operations.
The company hasn't accounted for interest provisions according to the MSMED Act, 2006. It has also made payments to MSME vendors beyond the contractual time limit specified in the Act.
Revenue from government-sponsored health schemes is crucial for the company. Any adverse changes in regulations or government policies related to these schemes could harm the company's business, financial results, and prospects.
Maitreya Medicare is yet to apply for approvals and licenses for its Valsad hospital. A delay in obtaining these approvals could impact the company's revenues, credibility, and future plans.
Maitreya Medicare's operations are concentrated in Surat, Gujarat, and are vulnerable to localized social unrest and natural calamities.
Maitreya Medicare's revenue heavily depends on specific medical specialties like cardiology, neurology, orthopedics, and general medicine. Any significant impact on these fields could significantly affect its financial condition and results.
Maitreya Medicare relies on a limited number of external suppliers for medicines and consumables. Delays or failures in product delivery may harm the company's business, profitability, and reputation.
Unsecured loans totaling Rs. 1.10 crores were outstanding as of March 31, 2023.
Maintaining sufficient bed occupancy rates is critical to generate adequate returns on capital expenditure. Failing to do so may harm operating efficiencies and profitability.
Maitreya Medicare derives a substantial portion of its revenue from tie-up arrangements with governmental organizations, insurance companies, third-party administrators, and corporations. Losing major customers could significantly impact the company's operations and profitability.
Maitreya Medicare has experienced negative cash flows in the past and may continue to do so in the future, which could affect its ability to operate and implement growth plans, impacting its financial condition.
Maitreya Medicare has contingent liabilities totaling Rs. 0.40 crores as of September 30, 2023, which may affect its financial condition and results of operations.